The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.
 
Helena Alexandra Yu
Consulting or Advisory Role - Clovis Oncology
Research Funding - Astellas Pharma; AstraZeneca; Clovis Oncology; Incyte; Pfizer
 
Geoffrey R. Oxnard
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - Patent pending
 
Alexander I. Spira
Research Funding - Astellas Pharma (Inst)
 
Leora Horn
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clovis Oncology; Helix BioPharma; Merck; Puma Biotechnology
Research Funding - Astellas Pharma (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Jared Weiss
Stock and Other Ownership Interests - Pharmacyclics
Consulting or Advisory Role - AstraZeneca; Biodesix; Clovis Oncology
Research Funding - Acceleron Pharma; Astellas Pharma; Celgene; GlaxoSmithKline; MedImmune; Pfizer
 
Yan Feng
Research Funding - Astellas Pharma
 
Howard Jack West
Honoraria - Celgene; Foundation Medicine; Genentech/Roche; Merck; Novartis; Pfizer
Consulting or Advisory Role - Celgene; Foundation Medicine; Genentech/Roche; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Celgene; Foundation Medicine; Genentech/Roche; Merck; Novartis; Novartis
 
Giuseppe Giaccone
Consulting or Advisory Role - Astex Pharmaceuticals; AVEO; Boehringer Ingelheim; Clovis Oncology
 
Tracey L. Evans
Honoraria - Celgene; Genentech; Genentech (I); Lilly
Consulting or Advisory Role - Celgene; Genentech; Genentech (I); Lilly
Speakers' Bureau - Genentech (I)
Research Funding - Sanofi
Travel, Accommodations, Expenses - Celgene; Genentech; Genentech (I); Lilly; Sanofi
 
Ronan Joseph Kelly
Consulting or Advisory Role - Lilly; Novartis
 
Tanya Fleege
Employment - Astellas Pharma
 
Srinivasu Poondru
Employment - Astellas Pharma
 
Fei Jie
Employment - Astellas Pharma
 
Koji Aoyama
Employment - Astellas Pharma
 
Margaret A. Foley
Employment - Astellas Pharma
 
Debbie Whitcomb
Employment - Astellas Pharma
 
Anne Therese Keating
Employment - Astellas Pharma
 
Andrew P. Krivoshik
Employment - Astellas Pharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Johnson & Johnson (I); Merck (I)
Patents, Royalties, Other Intellectual Property - U.S. Patent Application 20090149461 11 June 2009 Method of Treating Cancer (U.S. Provisional Application Ser. No. 61/058,113, filed Jun. 2, 2008; U.S. Provisional Application Ser. No. 60/992,857, filed Dec. 6, 2007). European Patent Office Application 08 (Inst)
Travel, Accommodations, Expenses - Astellas Pharma